Whille a substantial portion of cancer research is aimed at providing the best level of treatment to the afflicted patient, investigating the side effects and toxicity of the various therapies has not received much focus. Led by Dr. Charles Cleeland, McCullough Professor of Cancer Research at the University of Texas Anderson Cancer Center, a panel of clinicians, researchers, and representatives from advocacy groups, federal agencies, and the pharmaceutical industry was recently formed "to identify gaps in cancer treatment toxicity research and provide direction for future action." In the course of its investigations, the panel has seen how toxicity from cancer therapy affects one's treatment regimen and survival. Developing a strategy to implement toxicity phenotypes is thus seen as an immediate need to combat these adverse effects.
Further information on this study can be found here.
Study mentioned: Cleeland CS et al. Reducing the toxicity of cancer therapy: Recognizing needs, taking action. Nat Rev Clin Oncol. 2012 Jul 3 [Epub ahead of print]. PMID: 22751283
No comments:
Post a Comment